
Opinion|Videos|June 4, 2024
Long-Term Outcomes with Ruxolitinib in Polycythemia Vera
Downstream impacts of ruxolitinib in polycythemia vera treatment are illustrated by a panel of medical experts.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5






























